Filing Flows › Metagenomi Therapeutics (MGX) › Q4 2025 › vs Q3 2025
Metagenomi Therapeutics (MGX) Q4 2025 vs Q3 2025 (quarter over quarter)
Metagenomi Therapeutics's revenue fell $4.7M (-55%) from $8.7M in Q3 2025 to $3.9M in Q4 2025.
Metagenomi Therapeutics, Q4 2025: revenue $3.9M (-59% year over year), operating margin -623.0%, net loss $22.5M, operating cash flow −$23.5M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q4 2025 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.9M | $8.7M | −$4.7M | -55% |
| Other income, net | $1.9M | $2.2M | −$339K | -15% |
| Net loss | $22.5M | $20.4M | $2.1M | +10% |
| Costs & expenses | $28.3M | $31.5M | −$3.2M | -10% |
| Operating costs | $28.3M | $31.5M | −$3.2M | -10% |
| Income tax | $34K | −$234K | $268K | — |
| Research & development | $21.5M | $25.3M | −$3.8M | -15% |
| General & admin | $6.8M | $6.2M | $562K | +9% |
| Operating cash sources | $27.5M | $25.6M | $2.0M | +8% |
| Depreciation | $1.3M | $1.3M | −$24K | -2% |
| Share-based compensation | $2.7M | $3.0M | −$316K | -10% |
| Cash used in operations | $23.5M | $21.3M | $2.3M | +11% |
| Net loss absorbed | $22.5M | $20.4M | $2.1M | +10% |
| Working capital & other | $5.0M | $5.2M | −$182K | -4% |
Questions
How much did Metagenomi Therapeutics's revenue grow quarter over quarter in Q4 2025?
Metagenomi Therapeutics's revenue fell $4.7M (-55%) from $8.7M in Q3 2025 to $3.9M in Q4 2025.